Manufacturer of Controlled Substances; Notice of Application, 77850 [2011-32045]
Download as PDF
<![CDATA[
77850
Federal Register / Vol. 76, No. 240 / Wednesday, December 14, 2011 / Notices
marked ‘‘Privacy Act Request.’’ Include
in the request your full name and
complete address. The requester must
sign the request; and, to verify it, the
signature must be notarized or
submitted under 28 U.S.C. 1746, a law
that permits statements to be made
under penalty of perjury as a substitute
for notarization. You may submit any
other identifying data you wish to
furnish to assist in making a proper
search of the system. Requests for access
to information must be addressed to the
Record Information Dissemination
Section, Federal Bureau of Investigation,
170 Marcel Drive, Winchester, Virginia
22602 or faxed to (540) 868–4992.
mstockstill on DSK4VPTVN1PROD with NOTICES
CONTESTING RECORD PROCEDURES:
Because this system contains
classified intelligence and law
enforcement information related to the
government’s counterterrorism, law
enforcement and intelligence programs,
records in this system are exempt from
notification, access, and amendment to
the extent permitted by subsections (j)
and (k) of the Privacy Act (5 U.S.C.
552a). Requests for amendment should
be addressed to the FBI at the address
and according to the requirements set
forth above under the heading ‘‘Record
Access Procedures.’’ If, however,
individuals are experiencing repeated
delays or difficulties during a
government screening process and
believe that this might be related to
terrorist watch list information, they
may contact the Federal agency that is
conducting the screening process in
question (‘‘screening agency’’). The
screening agency is in the best position
to determine if a particular problem
relates to a terrorist watch list entry or
is due to some other cause, such as a
criminal history, an immigration
violation or random screening. Some
individuals also experience repeated
delays during screening because their
names and/or other identifying data,
such as dates of birth, are similar to
those of known or suspected terrorists.
These individuals, referred to as
‘‘misidentified persons,’’ often believe
that they themselves are on a terrorist
watch list, when in fact they only bear
a similarity in name or other identifier
to an individual on the list. Most
screening agencies have or are
developing procedures to expedite the
clearance of misidentified persons
during screening. By contacting the
screening agency with a complaint,
individuals will be able to take
advantage of the procedures available to
help misidentified persons and others
experiencing screening problems. Check
the agency’s requirements for
submitting complaints but, at a
VerDate Mar<15>2010
15:14 Dec 13, 2011
Jkt 226001
minimum, individuals should describe
in as much detail as possible the
problem they are having, including
dates and locations of screening, and
provide sufficient information to
identify themselves, such as full name,
citizenship status, and date and place of
birth. The TSC assists the screening
agency in resolving any screening
complaints that may relate to terrorist
watch list information, but does not
receive or respond to individual
complaints directly. However, if TSC
receives any such complaints, TSC will
forward them to the appropriate
screening agency. Additional
information about the redress process
and how to file a complaint with a
screening agency is available on TSC’s
Web site at https://www.fbi.gov/about-us/
nsb/tsc/tsc_redress.
RECORD SOURCE CATEGORIES:
Information in this system is obtained
from individuals covered by the system,
public sources, agencies and private
sector entities conducting terrorism
screening, law enforcement and
intelligence agency record systems,
government databases, and foreign
governments.
SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS
OF THE ACT:
The Attorney General has exempted
this system from subsections (c)(3) and
(4), (d)(1), (2), (3) and (4), (e)(1), (2), (3),
(5) and (8), and (g) of the Privacy Act
pursuant to 5 U.S.C. 552a(j) and (k).
These exemptions apply only to the
extent that information in the system is
subject to exemption pursuant to 5
U.S.C. 552a(j) and (k). Rules have been
promulgated in accordance with the
requirements of 5 U.S.C. 553(b), (c) and
(e) and are located at 28 CFR 16.96.
[FR Doc. 2011–32074 Filed 12–13–11; 8:45 am]
Drug
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
Schedule
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone,
and is not for commercial distribution.
The company plans to manufacture
Hydromorphone HCL for sale to other
manufacturers, and to manufacture
other controlled substances for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 13, 2012.
Dated: December 2, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–32045 Filed 12–13–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2011–0858]
Permit-Required Confined Spaces;
Extension of the Office of Management
and Budget’s (OMB) Approval of
Information Collection (Paperwork)
Requirements
BILLING CODE 4410–02–P
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Request for public comments.
DEPARTMENT OF JUSTICE
SUMMARY:
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 8, 2011, Halo
Pharmaceutical Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
AGENCY:
OSHA solicits public
comments concerning its proposal to
extend OMB approval of the
information collection requirements
contained in the Standard on PermitRequired Confined Spaces (29 CFR
1910.146). The purpose of the
information is to ensure that employers
systematically evaluate the dangers in
permit spaces before entry is attempted,
and to ensure that adequate measures
are taken to make the spaces safe for
entry.
Comments must be submitted
(postmarked, sent, or received) by
February 13, 2012.
DATES:
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 76, Number 240 (Wednesday, December 14, 2011)]
[Notices]
[Page 77850]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-32045]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 8, 2011, Halo
Pharmaceutical Inc., 30 North Jefferson Road, Whippany, New Jersey
07981, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
Dihydromorphine is an intermediate in the manufacture of
Hydromorphone, and is not for commercial distribution. The company
plans to manufacture Hydromorphone HCL for sale to other manufacturers,
and to manufacture other controlled substances for distribution to its
customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 13, 2012.
Dated: December 2, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-32045 Filed 12-13-11; 8:45 am]
BILLING CODE 4410-09-P
